Supporting this, breast cancer cells preincubated with the proteasome inhibitor MG-132 before treatment with doxorubicin displayed reduced nuclear and enhanced cytoplasmic levels of YB-1 (visualized with a C-terminal-targeting antibody; Figure 3), compared to cells treated with doxorubicin alone (van Roeyen et al., 2013). This evidence concerns the gene YBX1 and breast carcinoma.